Ingestible Sensors Could Help Diagnose Gut Disorders
Researchers at RMIT have successfully completed phase one human trials of ingestible capsules that have the potential to revolutionise the prevention and diagnosis of gut disorders and diseases.
The research team, led by the pills’ co-inventor Distinguished Professor Kourosh Kalantar-zadeh, tested the ingestible smart capsules (the size of a vitamin pill) that journey through and measure gas levels in the gastrointestinal tract.
One in five people will suffer from a gastrointestinal disorder in their lifetime, with 30 per cent of patients remaining undiagnosed. RMIT is one of the leading universities in the world researching the development of ingestible sensors.
The ingestible technology has demonstrated several thousand -times more sensitivity to gut gases than alternative techniques.
“Currently, one of the only methods for diagnosing gut disorders, such as mal-absorption of carbohydrates, irritable bowel syndrome and inflammable bowel disease, is to measure hydrogen concentrations in the breath,” Kalantar-zadeh said.
“However, breath tests are mired by a lack of sensitivity and specificity and are unable to provide the necessary gold standard for diagnosis.”
Co-inventor Dr Kyle Berean said: “Ingestible sensors also offer a reliable diagnostic tool for colon cancer, meaning that people won’t have to undergo colonoscopies in future.”
A key finding from the initial trials was just how safe the new technology is.
“Smart pills are harmless and there is no risk of capsule retention,” Berean said.
An added advantage is that the capsules can be synched with smartphones, meaning results are easily accessible by users and doctors online.
The potential applications from this technology are profound.
“The sensors allow us to measure all the fluids and gases in the gut giving us a multidimensional picture of the human body,” Kalantar-zadeh said. “Gas sensing is just the beginning.”
The human trials were undertaken with colleagues from Monash University, who Kalantar-zadeh was quick to praise.
“We have been lucky to have Monash medical academics helping us on this journey,” he said. “Without their input we would not be able to proceed.”
The outcomes of the human trials will be presented next month in Chicago at Digestive Disease Week (DDW), the most significant annual gathering of gastroenterologists and food scientists in the world.
Enterome and Nestlé Health Sciences Launch New Diagnostics CompanyNews
Enterome and Nestlé Health Sciences join to create Microbiome Diagnostics Partners, a company that will enable the development and diagnostics for multiple diseases including inflammatory bowel diseases (IBD) and liver diseases.READ MORE
Material From Shellfish Boosts Sensitivity of Diagnostic TestsNews
By adding polydopamine at a key step, the sensitivity of diagnostic tests and bioassays can be increased by as many as 100 to 1,000 times.READ MORE
Comments | 0 ADD COMMENT
EMBL Course: Techniques for Mammary Gland Research
Mar 05 - Mar 09, 2018